Skip to main content
SpringerLink
Log in

Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Casadevall N, Durieux P, Dubois S et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321–327

    Article  CAS  PubMed  Google Scholar 

  2. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al (2003) A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037–1046

    Article  CAS  PubMed  Google Scholar 

  3. Seipelt et al (2000) Cytokine therapy for myelodysplastic syndrome. Curr Opin Hematol 7:156–160

    Article  CAS  PubMed  Google Scholar 

  4. Kasper C, Zahner J, Sayer HG (2002) Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol 128:497–502

    Google Scholar 

  5. Musto P, Sanpaolo G, D’Arena G et al (2001) Adding growth factors or IL-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 86:44–51

    CAS  PubMed  Google Scholar 

  6. Tehranchi R, Fadeel B, Forsblom AM et al (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101:1080–1086

    Article  CAS  PubMed  Google Scholar 

  7. Rigolin GM, Porta MD, Ciccone M et al (2004) In patients with myelodysplastic syndromes response to rhEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 126:501–507

    Article  CAS  PubMed  Google Scholar 

  8. Cheson BD, Bennett JM, Kantarjian H et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671–3674

    CAS  PubMed  Google Scholar 

  9. Musto P, Lanza F, Balleari E et al (2004) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204–209

    Article  Google Scholar 

  10. Spiriti MAA, Latagliata R, Niscola P et al (2005) Impact of a new dosing regimen of epoetin alfa on quality of life an anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84:167–176

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Medical Center Offenburg, Ebertplatz 12, 77654, Offenburg, Germany

    Andreas Jakob & Friedrich W. Hirsch

  2. Department of Hematology and Oncology, Medical Center, University Hospital Freiburg, Hugestetterstr. 55, 79106, Freiburg, Germany

    Monika Engelhardt

Authors
  1. Andreas Jakob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Friedrich W. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monika Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Engelhardt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jakob, A., Hirsch, F.W. & Engelhardt, M. Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim. Ann Hematol 84, 694–695 (2005). https://doi.org/10.1007/s00277-005-1060-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1060-2

Keywords

Search

Navigation